Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Herpes Simplex Virus Type 1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Herpes Simplex Virus Type 1. Displaying page 1 of 1.
    EudraCT Number: 2021-003586-35 Sponsor Protocol Number: 215336 Start Date*: 2022-01-25
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase I/II, observer-blind, randomised, placebo controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV-targeted immunotherapy in healthy parti...
    Medical condition: Recurrent genital herpes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10018150 Genital herpes PT
    21.1 10021881 - Infections and infestations 10073931 Genital herpes simplex PT
    24.0 10021881 - Infections and infestations 10084891 Anal herpes LLT
    20.1 10021881 - Infections and infestations 10054225 Anogenital herpes LLT
    20.1 10021881 - Infections and infestations 10018151 Genital herpes, unspecified LLT
    20.0 10021881 - Infections and infestations 10019937 Herpes genital LLT
    20.0 10021881 - Infections and infestations 10019938 Herpes genitalis LLT
    20.0 10021881 - Infections and infestations 10019997 Herpetic infection of penis LLT
    20.1 10021881 - Infections and infestations 10020003 Herpetic ulceration of vulva LLT
    20.1 10021881 - Infections and infestations 10020004 Herpetic vulvovaginitis LLT
    21.1 10021881 - Infections and infestations 10065050 Perianal herpes simplex LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Trial now transitioned) ES (Ongoing) EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004316-31 Sponsor Protocol Number: FPP4-DE-401 Start Date*: 2009-02-23
    Sponsor Name:Novartis Consumer Health S.A.
    Full Title: A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions ...
    Medical condition: Cold Sores caused by the herpes simplex virus (HSV) type 1.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049352 Cold sores lip LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006940-69 Sponsor Protocol Number: 601 Start Date*: 2010-05-20
    Sponsor Name:Lund University Hospital
    Full Title: Add-on treatment of mental illness with anti-viral medicine
    Medical condition: Schizophrenia, bipolar disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000033-41 Sponsor Protocol Number: AMEN1 Start Date*: 2020-02-17
    Sponsor Name:Aalborg University Hospital
    Full Title: Aciclovir for HSV-2 meningitis: A double-blind randomised controlled trial (AMEN)
    Medical condition: Viral meningitis caused by Herpes simplex virus 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10047469 Viral meningitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003953-34 Sponsor Protocol Number: 101-001 Start Date*: 2009-12-14
    Sponsor Name:D2 Derma Europe Ltd.
    Full Title: A randomized, placebo-controlled, active comparator, observer-blinded multicentre phase II trial to evaluate the efficacy and safety of D2D001 in the treatment of HSV type 1 infection in the region...
    Medical condition: Herpes simplex virus type 1 infection in the region of the mouth and the openings of the nose
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002268-26 Sponsor Protocol Number: CTN240 Start Date*: 2013-01-02
    Sponsor Name:University Health Network, Toronto General Hospital
    Full Title: Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE)
    Medical condition: Coinfection of Human Immunodeficiency Virus and Herpes Simplex Virus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024496-37 Sponsor Protocol Number: 1716-12 Start Date*: 2012-05-04
    Sponsor Name:Virttu Biologics Limited
    Full Title: A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEAR...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005795-41 Sponsor Protocol Number: IELSG27 Start Date*: 2006-09-12
    Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)
    Full Title: A CLINICO-PATHOLOGICAL PHASE II STUDY WITH TRANSLATIONAL ELEMENTS TO INVESTIGATE THE POSSIBLE INFECTIVE CAUSES OF NON-HODGKIN LYMPHOMA OF THE OCULAR ADNEXAE WITH PARTICULAR REFERENCE TO CHLAMYDIA ...
    Medical condition: MALT lymphoma of the ocular adnexae
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061850 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005023-33 Sponsor Protocol Number: 1182.99 Start Date*: 2007-03-15
    Sponsor Name:Boehringer Ingelheim France SAS
    Full Title: Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e...
    Medical condition: Treatment with three-class (NRTI, NNRTI, and PI) experienced HIV positive patients with HCV or HBV co-infection, with a minimum of 3-months duration for each class and have documented resistance to...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005264-86 Sponsor Protocol Number: 1182.98 Start Date*: 2007-02-21
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a p...
    Medical condition: The objective of this study is to demonstrate the safety and efficacy of TPV/r among a racially diverse HIV-positive population of females and males who are three-class (NRTI, NNRTI, and PI) experi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024247-32 Sponsor Protocol Number: 1263-203 Start Date*: 2012-03-09
    Sponsor Name:VIROPHARMA INCORPORATED
    Full Title: A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WH...
    Medical condition: CMV INFECTIONS IN TRANSPLANT RECIPIENTS
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10021819 Infection in marrow transplant recipients LLT
    14.1 100000004862 10021829 Infection in solid organ transplant recipients LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) AT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA